ClinVar Genomic variation as it relates to human health
NM_007294.4(BRCA1):c.5277+1G>A
No data submitted for somatic clinical impact
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NM_007294.4(BRCA1):c.5277+1G>A
Variation ID: 37654 Accession: VCV000037654.104
- Type and length
-
single nucleotide variant, 1 bp
- Location
-
Cytogenetic: 17q21.31 17: 43057051 (GRCh38) [ NCBI UCSC ] 17: 41209068 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Apr 1, 2014 Jun 17, 2024 Aug 10, 2015 - HGVS
- ... more HGVS ... less HGVS
- Protein change
- Other names
- IVS19+1 G>A
- IVS20+1G>A
- Canonical SPDI
- NC_000017.11:43057050:C:T
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
- sequence_variant_affecting_splicing Sequence Ontology [SO:1000071]
- Intron inclusion between exons 18 & 19, based on review of RNA-seq in MDA-MB-436 cancer cell line which has BRCA1 NM_007297.3:c.5136+1G>A variant. [submitted by MutSpliceDB: a database of splice sites variants effects on splicing, NIH]
- functionally_abnormal Sequence Ontology [SO:0002218]
- The saturation genome editing (SGE) assay for BRCA1 NM_007294.3:c.5277+1G>A, a CANONICAL SPLICE variant, produced a function score of -2.56, corresponding to a functional classification of LOSS_OF_FUNCTION. SGE function score ranges for classification are as follows: ‘functional’, score > -0.748; ‘intermediate’, -0.748 > score > -1.328; ‘non-functional’, score < -1.328. The median synonymous SNV scored 0.0 and the median nonsense SNV scored -2.12. [submitted by Brotman Baty Institute, University of Washington]
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
-
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
-
Genes
Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
---|---|---|---|---|---|---|
HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
BRCA1 | Sufficient evidence for dosage pathogenicity | No evidence available |
GRCh38 GRCh37 |
13037 | 14843 |
Conditions - Germline
Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
---|---|---|---|---|
Pathogenic (12) |
reviewed by expert panel
|
Aug 10, 2015 | RCV000031235.27 | |
Pathogenic (4) |
criteria provided, multiple submitters, no conflicts
|
Dec 30, 2023 | RCV000074601.31 | |
Pathogenic (3) |
criteria provided, multiple submitters, no conflicts
|
May 10, 2023 | RCV000131865.17 | |
Pathogenic (6) |
criteria provided, multiple submitters, no conflicts
|
Oct 25, 2021 | RCV000235135.23 | |
Pathogenic (1) |
criteria provided, single submitter
|
May 24, 2017 | RCV000507129.15 | |
Pathogenic (1) |
no assertion criteria provided
|
Jan 22, 2016 | RCV000735562.9 | |
Pathogenic (1) |
no assertion criteria provided
|
Sep 1, 2019 | RCV001171438.11 | |
Pathogenic (1) |
no assertion criteria provided
|
- | RCV001353526.9 |
Submissions - Germline
Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
---|---|---|---|---|---|
Pathogenic
(Aug 10, 2015)
|
reviewed by expert panel
Method: curation
|
Breast-ovarian cancer, familial 1
Affected status: unknown
Allele origin:
germline
|
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)
Accession: SCV000244394.1
First in ClinVar: Sep 29, 2015 Last updated: Sep 29, 2015 |
Comment:
IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 5 based on … (more)
IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 5 based on posterior probability = 1 (less)
|
|
Pathogenic
(May 24, 2017)
|
criteria provided, single submitter
Method: clinical testing
|
not specified
Affected status: unknown
Allele origin:
germline
|
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Accession: SCV000602686.1
First in ClinVar: Sep 30, 2017 Last updated: Sep 30, 2017 |
|
|
Pathogenic
(Aug 19, 2014)
|
criteria provided, single submitter
Method: literature only
|
Breast-ovarian cancer, familial 1
(Autosomal dominant inheritance)
Affected status: unknown
Allele origin:
unknown
|
Counsyl
Accession: SCV000220602.2
First in ClinVar: Mar 29, 2015 Last updated: Dec 24, 2022 |
|
|
Pathogenic
(Feb 20, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Revvity Omics, Revvity
Accession: SCV002020145.3
First in ClinVar: Nov 29, 2021 Last updated: Feb 04, 2024 |
|
|
Pathogenic
(Dec 30, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Hereditary breast ovarian cancer syndrome
Affected status: unknown
Allele origin:
germline
|
Labcorp Genetics (formerly Invitae), Labcorp
Accession: SCV000076909.13
First in ClinVar: Jul 03, 2013 Last updated: Feb 20, 2024 |
Comment:
This sequence change affects a donor splice site in intron 19 of the BRCA1 gene. RNA analysis indicates that disruption of this splice site induces … (more)
This sequence change affects a donor splice site in intron 19 of the BRCA1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with breast or ovarian cancer (PMID: 11149413, 16683254, 19949876). ClinVar contains an entry for this variant (Variation ID: 37654). Based on a multifactorial likelihood algorithm using genetic, in silico, and/or statistical data, this variant has been determined to have a high probability of being pathogenic (PMID: 17924331). Studies have shown that disruption of this splice site results in activation of a cryptic splice site in intron 19 or skipping of exon 19 (also known as exon 20) and introduces a premature termination codon (PMID: 24667779; Invitae). The resulting mRNA is expected to undergo nonsense-mediated decay. For these reasons, this variant has been classified as Pathogenic. (less)
|
|
Pathogenic
(Mar 13, 2024)
|
criteria provided, single submitter
Method: clinical testing
|
Breast-ovarian cancer, familial, susceptibility to, 1
Affected status: unknown
Allele origin:
unknown
|
Baylor Genetics
Accession: SCV004215054.2
First in ClinVar: Dec 30, 2023 Last updated: Jun 17, 2024 |
|
|
Pathogenic
(Oct 02, 2015)
|
criteria provided, single submitter
Method: clinical testing
|
Breast-ovarian cancer, familial, susceptibility to, 1
Affected status: unknown
Allele origin:
germline
|
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge
Accession: SCV000326234.4
First in ClinVar: Sep 29, 2015 Last updated: Dec 11, 2022 |
|
|
Pathogenic
(Oct 25, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Not Provided
Affected status: yes
Allele origin:
germline
|
GeneDx
Accession: SCV000108686.16
First in ClinVar: Dec 10, 2013 Last updated: Mar 04, 2023 |
Comment:
Canonical splice site variant demonstrated to result in an in-frame deletion of a critical region (Tesoriero 2005, Sanz 2010, Steffensen 2014); Multifactorial studies suggest this … (more)
Canonical splice site variant demonstrated to result in an in-frame deletion of a critical region (Tesoriero 2005, Sanz 2010, Steffensen 2014); Multifactorial studies suggest this variant is associated with breast and ovarian cancer (Easton 2007, Lindor 2012); Published functional studies demonstrate a damaging effect: classified as non-functional based on a saturation genome editing (SGE) assay measuring cell growth (Findlay 2018); Not observed in large population cohorts (Lek 2016); Deletions involving coding exons in this gene are frequently reported as pathogenic, regardless of frame prediction (Stenson 2014); Observed in individuals with early-onset or familial breast and/or ovarian cancer (de la Hoya 2001, Diez 2003, van Harssel 2010, Lara 2012); Classified as pathogenic by a well-established clinical consortium and/or database (ClinVar SCV000244394.1; Landrum 2016); Also known as 5396+1G>A or IVS20+1G>A; This variant is associated with the following publications: (PMID: 23348723, 23096355, 19593635, 20215541, 19949876, 18286383, 18528753, 25849179, 18298804, 26913838, 29446198, 17924331, 21990134, 25525159, 11149413, 12955716, 16211554, 25859162, 24667779, 28636540, 28477318, 28918466, 30209399, 30720863, 25085752, 32665702) (less)
|
|
Pathogenic
(May 10, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Hereditary cancer-predisposing syndrome
Affected status: unknown
Allele origin:
germline
|
Color Diagnostics, LLC DBA Color Health
Accession: SCV000292160.2
First in ClinVar: Jul 08, 2016 Last updated: Feb 14, 2024 |
Comment:
This variant causes a G to A nucleotide substitution at the +1 position of intron 19 of the BRCA1 gene. This variant is also known … (more)
This variant causes a G to A nucleotide substitution at the +1 position of intron 19 of the BRCA1 gene. This variant is also known as IVS20+1G>A by a legacy nomenclature in the literature. RNA studies have found that this variant results in the retention of 87 nucleotides from intron 19 and the skipping of exon 19, that are predicted to cause in-frame insertion of 29 amino acids in the BRCT domain and out-of-frame splicing, respectively (PMID: 16211554, 24667779, 31843900). A functional study has reported that this variant impacts BRCA1 function in a haploid cell proliferation assay (PMID: 30209399). This variant has been reported in several individuals affected with breast or ovarian cancer, one individual affected with peritoneal cancer (PMID: 14574155, 16211554, 20215541, 21913181, 23096355) and in at least four dozen suspected hereditary breast and ovarian cancer families (PMID: 11149413, 11597388, 11802209, 16683254, 19949876, 24285858), including one family in which this variant segregates with ovarian cancer in five members of one family (PMID: 16211554). This variant also has been detected in a breast cancer case-control meta-analysis in 8/60466 cases and 1/53461 unaffected individuals (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA1_000441). A multifactorial analysis has reported a family history likelihood ratio for pathogenicity of 11.1 (PMID: 17924331). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. (less)
|
|
Pathogenic
(Jul 19, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Breast-ovarian cancer, familial, susceptibility to, 1
(Autosomal dominant inheritance)
Affected status: unknown
Allele origin:
germline
|
All of Us Research Program, National Institutes of Health
Accession: SCV004834029.1
First in ClinVar: Apr 20, 2024 Last updated: Apr 20, 2024
Comment:
This study involves interpretation of variants in research participants for the purpose of population health screening. Participant phenotype was not available at the time of … (more)
This study involves interpretation of variants in research participants for the purpose of population health screening. Participant phenotype was not available at the time of variant classification. Additional details can be found in publication PMID: 35346344, PMCID: PMC8962531 (less)
|
Comment:
This variant causes a G to A nucleotide substitution at the +1 position of intron 19 of the BRCA1 gene. This variant is also known … (more)
This variant causes a G to A nucleotide substitution at the +1 position of intron 19 of the BRCA1 gene. This variant is also known as IVS20+1G>A by a legacy nomenclature in the literature. RNA studies have found that this variant results in the retention of 87 nucleotides from intron 19 and the skipping of exon 19, that are predicted to cause in-frame insertion of 29 amino acids in the BRCT domain and out-of-frame splicing, respectively (PMID: 16211554, 24667779, 31843900). A functional study has reported that this variant impacts BRCA1 function in a haploid cell proliferation assay (PMID: 30209399). This variant has been reported in several individuals affected with breast or ovarian cancer, one individual affected with peritoneal cancer (PMID: 14574155, 16211554, 20215541, 21913181, 23096355) and in at least four dozen suspected hereditary breast and ovarian cancer families (PMID: 11149413, 11597388, 11802209, 16683254, 19949876, 24285858), including one family in which this variant segregates with ovarian cancer in five members of one family (PMID: 16211554). This variant also has been detected in a breast cancer case-control meta-analysis in 8/60466 cases and 1/53461 unaffected individuals (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA1_000441). A multifactorial analysis has reported a family history likelihood ratio for pathogenicity of 11.1 (PMID: 17924331). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. (less)
Number of individuals with the variant: 1
|
|
Pathogenic
(Oct 08, 2014)
|
criteria provided, single submitter
Method: clinical testing
|
Breast-ovarian cancer, familial, susceptibility to, 1
Affected status: yes
Allele origin:
germline
|
Genome Diagnostics Laboratory, University Medical Center Utrecht
Study: VKGL Data-share Consensus
Accession: SCV000743373.1 First in ClinVar: Apr 09, 2018 Last updated: Apr 09, 2018 |
|
|
Pathogenic
(Sep 21, 2015)
|
criteria provided, single submitter
Method: clinical testing
|
Breast-ovarian cancer, familial, susceptibility to, 1
Affected status: yes
Allele origin:
germline
|
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Study: VKGL Data-share Consensus
Accession: SCV000744588.1 First in ClinVar: Apr 09, 2018 Last updated: Apr 09, 2018 |
|
|
Pathogenic
(Feb 25, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Hereditary breast ovarian cancer syndrome
Affected status: unknown
Allele origin:
germline
|
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Accession: SCV000699231.1
First in ClinVar: Dec 26, 2017 Last updated: Dec 26, 2017 |
Comment:
Variant summary: BRCA1 c.5277+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to … (more)
Variant summary: BRCA1 c.5277+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a 5' splicing donor site. These predictions have been confirmed by experimental evidence showing the variant to result in the skipping of exon 20 and generating a truncated protein (Tesoriero_2005). The variant was absent in 251494 control chromosomes. c.5277+1G>A has been reported in the literature in multiple individuals affected with Hereditary Breast And Ovarian Cancer Syndrome (eg Meindl_2002, Diez_2003, Tesoriero_2012, Lara_2012, Litton_2012, Brohet_2014, etc). 12 clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. (less)
|
|
Pathogenic
(Jul 01, 2015)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Quest Diagnostics Nichols Institute San Juan Capistrano
Accession: SCV000296332.4
First in ClinVar: Oct 09, 2016 Last updated: Jan 03, 2022 |
|
|
Pathogenic
(Nov 01, 2021)
|
criteria provided, single submitter
Method: research
|
Hereditary breast ovarian cancer syndrome
Affected status: yes
Allele origin:
germline
|
Genetics Program, Instituto Nacional de Cancer
Accession: SCV002515230.1
First in ClinVar: Nov 19, 2022 Last updated: Nov 19, 2022 |
Geographic origin: Brazil
|
|
Pathogenic
(Aug 05, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Hereditary cancer-predisposing syndrome
Affected status: unknown
Allele origin:
germline
|
Ambry Genetics
Accession: SCV000186920.8
First in ClinVar: Aug 06, 2014 Last updated: May 01, 2024 |
Comment:
The c.5277+1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide after coding exon 18 of the BRCA1 gene. This mutation has … (more)
The c.5277+1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide after coding exon 18 of the BRCA1 gene. This mutation has been identified in multiple breast and/or ovarian cancer families (de la Hoya M et al. Int. J. Cancer. 2001 Jan;91:137-40; Verhoog LC et al. Eur. J. Cancer. 2001 Nov;37:2082-90; Meindl A et al. Int. J. Cancer. 2002 Feb;97:472-80; Díez O et al Hum. Mutat. 2003 Oct;22:301-12; Piek JM et al. Fam. Cancer. 2003;2:73-8; Lara K et al. Biol. Res. 2012;45:117-30). This alteration has been classified as definitely pathogenic by multifactorial analysis, which integrates the following lines of evidence to produce a quantitative likelihood of pathogenicity: in silico prediction models, segregation with disease, tumor characteristics, and mutation co-occurrence (Easton DF et al. Am. J. Hum. Genet. 2007 Nov;81:873-83; Lindor NM et al. Hum. Mutat. 2012 Jan;33:8-21; Vallee MP et al. Hum. Mutat. 2012 Jan;33:22-8). Multiple RNA studies have demonstrated that this alteration results in abnormal splicing (Tesoriero AA et al. Hum. Mutat. 2005 Nov;26:495; Elstrodt F et al. Cancer Res. 2006 Jan;66:41-5; Steffensen AY et al. Eur. J. Hum. Genet. 2014 Dec;22:1362-8; Tesoriero AA et al. Hum. Mutat. 2014 Apr;35:511; Ambry internal data). One functional study found that this nucleotide substitution is deleterious in a high throughput genome editing haploid cell survival assay (Findlay GM et al. Nature, 2018 10;562:217-222). Of note, this mutation is also designated as IVS20+1G>A and 5396+1G>A in published literature. In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. (less)
|
|
Pathogenic
(-)
|
criteria provided, single submitter
Method: clinical testing
|
Breast-ovarian cancer, familial, susceptibility to, 1
(Autosomal dominant inheritance)
Affected status: yes
Allele origin:
germline
|
Neuberg Centre For Genomic Medicine, NCGM
Accession: SCV005042909.1
First in ClinVar: May 12, 2024 Last updated: May 12, 2024 |
Comment:
The invariant splice donor c.5277+1G>A variant in BRCA1 gene has been reported previously in heterozygous state in multiple individuals affected with Hereditary Breast and/or Ovarian … (more)
The invariant splice donor c.5277+1G>A variant in BRCA1 gene has been reported previously in heterozygous state in multiple individuals affected with Hereditary Breast and/or Ovarian cancer Steffensen AY, et al., 2014; van Harssel JJ, et al., 2010; van der Hout AH, et al., 2006. This variant has been known to segregate with disease. Functional studies indicate that this variant leads to skipping of exon 20 and creates a premature stop codon, proving a damaging effect Tesoriero AA, et al., 2005. The c.5277+1G>A variant is novel not in any individuals in gnomAD Exomes and 1000 Genomes. This variant has been reported to the ClinVar database as Pathogenic multiple submissions. Loss of function variants have been previously reported to be disease causing. For these reasons, this variant has been classified as Pathogenic. (less)
Clinical Features:
Neoplasm (present)
|
|
Pathogenic
(May 02, 2012)
|
no assertion criteria provided
Method: clinical testing
|
Breast-ovarian cancer, familial 1
Affected status: not provided
Allele origin:
germline
|
Sharing Clinical Reports Project (SCRP)
Accession: SCV000053836.6
First in ClinVar: Apr 04, 2013 Last updated: Sep 29, 2015 |
|
|
Pathogenic
(Sep 01, 2019)
|
no assertion criteria provided
Method: research
|
Hereditary breast and ovarian cancer syndrome
Breast-ovarian cancer, familial 1
Affected status: yes
Allele origin:
germline
|
King Laboratory, University of Washington
Accession: SCV001251349.1
First in ClinVar: Jun 08, 2020 Last updated: Jun 08, 2020
Comment:
Transcript analysis by cBROCA
|
|
|
Pathogenic
(-)
|
no assertion criteria provided
Method: clinical testing
|
Breast-ovarian cancer, familial, susceptibility to, 1
Affected status: yes
Allele origin:
germline
|
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV000733590.1 First in ClinVar: Apr 09, 2018 Last updated: Apr 09, 2018 |
|
|
Pathogenic
(Oct 30, 2017)
|
no assertion criteria provided
Method: clinical testing
|
Hereditary cancer-predisposing syndrome
Affected status: unknown
Allele origin:
germline
|
True Health Diagnostics
Accession: SCV000787910.1
First in ClinVar: Oct 21, 2017 Last updated: Oct 21, 2017 |
|
|
Pathogenic
(Dec 30, 1999)
|
no assertion criteria provided
Method: clinical testing
|
Breast-ovarian cancer, familial 1
Affected status: yes
Allele origin:
germline
|
Breast Cancer Information Core (BIC) (BRCA1)
Accession: SCV000145422.1
First in ClinVar: Apr 01, 2014 Last updated: Apr 01, 2014 |
Observation 1:
Number of individuals with the variant: 10
Observation 2:
Number of individuals with the variant: 10
Geographic origin: Netherlands
Observation 3:
Number of individuals with the variant: 1
Geographic origin: Venezuela
Observation 4:
Number of individuals with the variant: 17
Ethnicity/Population group: Caucasian
Geographic origin: Netherlands
Observation 5:
Number of individuals with the variant: 1
Ethnicity/Population group: Caucasian
Geographic origin: Spain
Observation 6:
Number of individuals with the variant: 1
Ethnicity/Population group: Dutch
Geographic origin: Canada
Observation 7:
Number of individuals with the variant: 1
Ethnicity/Population group: Latin American, Caribbean
Observation 8:
Number of individuals with the variant: 7
Ethnicity/Population group: Western European
Observation 9:
Number of individuals with the variant: 1
Ethnicity/Population group: Western Europeanan, Central/Eastern European
|
|
Pathogenic
(Jan 31, 2014)
|
no assertion criteria provided
Method: research
|
Hereditary breast ovarian cancer syndrome
Affected status: yes
Allele origin:
germline
|
Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto
Study: The Canadian Open Genetics Repository (COGR)
Accession: SCV000587485.1 First in ClinVar: Aug 05, 2017 Last updated: Aug 05, 2017 |
|
|
Pathogenic
(Jan 22, 2016)
|
no assertion criteria provided
Method: clinical testing
|
Breast and/or ovarian cancer
Affected status: unknown
Allele origin:
germline
|
Foulkes Cancer Genetics LDI, Lady Davis Institute for Medical Research
Study: The Canadian Open Genetics Repository (COGR)
Accession: SCV000863700.1 First in ClinVar: Dec 24, 2018 Last updated: Dec 24, 2018 |
|
|
Pathogenic
(-)
|
no assertion criteria provided
Method: clinical testing
|
Malignant tumor of breast
Affected status: yes
Allele origin:
unknown
|
Department of Pathology and Laboratory Medicine, Sinai Health System
Additional submitter:
Franklin by Genoox
Study: The Canadian Open Genetics Repository (COGR)
Accession: SCV000591605.2 First in ClinVar: Aug 27, 2017 Last updated: Apr 13, 2021 |
Comment:
The c.5277+1G>A variant has been previously reported in the literature in at least 5 of 3526 proband chromosomes in individuals with hereditary breast and ovarian … (more)
The c.5277+1G>A variant has been previously reported in the literature in at least 5 of 3526 proband chromosomes in individuals with hereditary breast and ovarian cancer (De La Hoya 2001, Sanz 2010, Diez 2003, Easton 2007, Tesoriero 2005). In one study, bilateral breast cancer was noted and the presence of other cancers in the family (Diez 2003). In two studies, disease status was noted in 6 individuals (1 with breast and 5 with ovarian) and the variant was shown to segregate with disease in at least one affected family member (Sanz 2010, Tesoriero 2005). Tesoriero et al. (2005) carried out functional studies and determined that this variant leads to two alternative products, one causing exon 20 skipping and leading to a premature stop codon at codon 1737 and the other having retention of exon 20 and leading to a stop codon at codon 1767. The variant was identified in the UMD database 3 times as causal and in the BIC database 43 times as being clinically important. Easton et al (2007) report this variant as having >10e11 odds in favour of causality. Furthermore, this variant occurs within the +1 position of the 3' consensus splice site and variants at this position are a known mechanism of mutation and the type of variant expected to cause the disorder. In addition, in-silico or computational prediction software (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predicts a greater than 10% difference in splicing in 5 of 5 different programs. In summary, based on the above information, this variant is classified as pathogenic. (less)
Number of individuals with the variant: 1
|
|
Pathogenic
(-)
|
no assertion criteria provided
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute
Additional submitter:
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV001906442.1 First in ClinVar: Sep 26, 2021 Last updated: Sep 26, 2021 |
|
|
Pathogenic
(-)
|
no assertion criteria provided
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Additional submitter:
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV001955091.1 First in ClinVar: Oct 02, 2021 Last updated: Oct 02, 2021 |
|
|
not provided
(-)
|
no classification provided
Method: in vitro
|
not provided
Affected status: not applicable
Allele origin:
not applicable
|
MutSpliceDB: a database of splice sites variants effects on splicing, NIH
Accession: SCV000925675.2
First in ClinVar: Jul 08, 2019 Last updated: Jul 08, 2019 |
Method: Based on review of RNA-seq data in sample with variant.
Result:
Intron inclusion between exons 18 & 19
|
|
not provided
(-)
|
no classification provided
Method: in vitro
|
Breast-ovarian cancer, familial 1
Affected status: not applicable
Allele origin:
not applicable
|
Brotman Baty Institute, University of Washington
Accession: SCV001242994.1
First in ClinVar: Apr 18, 2020 Last updated: Apr 18, 2020 |
Method: saturation genome editing in haploid cells
Result:
LOSS_OF_FUNCTION:-2.56476137333993
|
|
click to load more click to collapse |
Germline Functional Evidence
Functional
Help
The functional consequence of the variant, based on experimental evidence and provided by the submitter. consequence |
Method
Help
A brief description of the method used to determine the functional consequence of the variant. A citation for the method is included, when provided by the submitter. |
Result
Help
A brief description of the result of this method for this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting functional evidence for the germline classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
---|---|---|---|---|
sequence_variant_affecting_splicing
|
|
|
MutSpliceDB: a database of splice sites variants effects on splicing, NIH
Accession: SCV000925675.2
|
Comment:
Intron inclusion between exons 18 & 19, based on review of RNA-seq in MDA-MB-436 cancer cell line which has BRCA1 NM_007297.3:c.5136+1G>A variant.
|
functionally_abnormal
|
Method citation(s):
|
|
Brotman Baty Institute, University of Washington
Accession: SCV001242994.1
|
Comment:
The saturation genome editing (SGE) assay for BRCA1 NM_007294.3:c.5277+1G>A, a CANONICAL SPLICE variant, produced a function score of -2.56, corresponding to a functional classification of … (more)
The saturation genome editing (SGE) assay for BRCA1 NM_007294.3:c.5277+1G>A, a CANONICAL SPLICE variant, produced a function score of -2.56, corresponding to a functional classification of LOSS_OF_FUNCTION. SGE function score ranges for classification are as follows: ‘functional’, score > -0.748; ‘intermediate’, -0.748 > score > -1.328; ‘non-functional’, score < -1.328. The median synonymous SNV scored 0.0 and the median nonsense SNV scored -2.12. (less)
|
Citations for germline classification of this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service. | Matta BP | Scientific reports | 2022 | PMID: 36329109 |
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. | Breast Cancer Association Consortium | The New England journal of medicine | 2021 | PMID: 33471991 |
Characterization of splice-altering mutations in inherited predisposition to cancer. | Casadei S | Proceedings of the National Academy of Sciences of the United States of America | 2019 | PMID: 31843900 |
Accurate classification of BRCA1 variants with saturation genome editing. | Findlay GM | Nature | 2018 | PMID: 30209399 |
Functional characterization of BRCA1 gene variants by mini-gene splicing assay. | Steffensen AY | European journal of human genetics : EJHG | 2014 | PMID: 24667779 |
Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. | Brohet RM | Journal of medical genetics | 2014 | PMID: 24285858 |
Prediction of mutant mRNA splice isoforms by information theory-based exon definition. | Mucaki EJ | Human mutation | 2013 | PMID: 23348723 |
BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela. | Lara K | Biological research | 2012 | PMID: 23096355 |
A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). | Lindor NM | Human mutation | 2012 | PMID: 21990134 |
Earlier age of onset of BRCA mutation-related cancers in subsequent generations. | Litton JK | Cancer | 2012 | PMID: 21913181 |
A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. | Sanz DJ | Clinical cancer research : an official journal of the American Association for Cancer Research | 2010 | PMID: 20215541 |
Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection. | van Harssel JJ | Familial cancer | 2010 | PMID: 19949876 |
A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. | Easton DF | American journal of human genetics | 2007 | PMID: 17924331 |
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. | van der Hout AH | Human mutation | 2006 | PMID: 16683254 |
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. | Elstrodt F | Cancer research | 2006 | PMID: 16397213 |
Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families. | Tesoriero AA | Human mutation | 2005 | PMID: 16211554 |
Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. | Piek JM | Familial cancer | 2003 | PMID: 14574155 |
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. | Díez O | Human mutation | 2003 | PMID: 12955716 |
Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. | Meindl A | International journal of cancer | 2002 | PMID: 11802209 |
Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. | Verhoog LC | European journal of cancer (Oxford, England : 1990) | 2001 | PMID: 11597388 |
Spanish family study on hereditary breast and/or ovarian cancer: analysis of the BRCA1 gene. | de la Hoya M | International journal of cancer | 2001 | PMID: 11149413 |
http://hci-exlovd.hci.utah.edu/variants.php?select_db=BRCA1&action=search_all&search_Variant%2FDNA=c.5277+1G%3EA | - | - | - | - |
https://brb.nci.nih.gov/cgi-bin/splicing/splicing_evidence.cgi?caid=CA003419 | - | - | - | - |
https://sge.gs.washington.edu/BRCA1/ | - | - | - | - |
click to load more click to collapse |
Text-mined citations for rs80358150 ...
HelpRecord last updated Oct 13, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.